More than 15 generic medications, including injectables and tablets, have been debarred since January by Tamil Nadu Medical Services Corporation...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

TUESDAY, Oct. 1, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Pulmonary Infections pipeline constitutes 10+ key companies...

AUSTIN, TX, September 25, 2024– IntraBio Inc., a leader in the discovery and development of innovative drugs for rare neurodegenerative...

On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide,...

Quality issues were found in several generic drugs by regulatory agencies in Tamil Nadu and Maharashtra. Alerts have been issued in the media for...

Highlights: EBGLYSS targets IL-13 to reduce eczema inflammation and itching FDA approval was based on successful

The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.